My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

85.04 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
Why AstraZeneca Stock Was Topping the Market on Tuesday
Investors were clearly impressed by the company's second-quarter beats, especially the one on the bottom line. 
Via The Motley Fool
AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook
AstraZeneca posted $14.46 billion in Q2 revenue, reaffirming its 2025 outlook as the FDA advances Imfinzi in gastric cancer. 
Via Benzinga
Topics Earnings
AstraZeneca results: H1 and Q2 2025
From AstraZeneca
Via Business Wire
AstraZeneca Q2 Beats On Cancer Drug Sales, Maintains Guidance — Shares Rise Premarket As Retail Cheers
Via Stocktwits
Earnings Scheduled For July 29, 2025
 
Via Benzinga
Why Is Micro-Cap AIM ImmunoTech Stock Surging?
AIM ImmunoTech shares rise after DURIPANC trial data show superior survival and safety in metastatic pancreatic cancer patients. 
Via Benzinga
AstraZeneca Earnings Preview
 
Via Benzinga
AstraZeneca Stock Rises As Experimental Drug Lowers Blood Pressure In Late-Stage Study, Retail’s Yet To React
Via Stocktwits
IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers
From AstraZeneca
Via Business Wire
5 Dividend Stocks to Hold for the Next 20 Years
Discover five unstoppable dividend stocks that could pay you for life, and why I wouldn't sell any of them! 
Via The Motley Fool
AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate
AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR antibody-positive gMG. 
Via Benzinga
What's Driving the Market Sentiment Around AstraZeneca?
 
Via Benzinga
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs. 
Via Benzinga
Topics Government
Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy
Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline. 
Via Benzinga
Dow Futures Edge Lower As Investors Exercise Caution After S&P 500’s Record High: GM, KO, NXPI, AZN Among Stocks To Watch
While Dow Jones futures were down 0.01% at the time of writing, the S&P 500 futures fell 0.09%. 
Via Stocktwits
Topics ETFs Government Stocks
AstraZeneca Bets Big On America With $50B Investment, New Virginia Hub Plans Amid Pharma Tariff Jitters
At the center of the company’s plan is a new, multi-billion-dollar manufacturing facility in Virginia. 
Via Stocktwits
Topics Artificial Intelligence Government World Trade
AstraZeneca's Multi-Billion Dollar Cancer Drug Tagrisso Improves Overall Survival In Patients With Advanced Lung Cancer
AstraZeneca's Tagrisso with chemo significantly improves survival and progression-free outcomes in EGFR-mutant NSCLC, final trial data shows. 
Via Benzinga
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
From AstraZeneca
Via Business Wire
TAGRISSO® (osimertinib) plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer
From AstraZeneca
Via Business Wire
JPMorgan Goes Global With HOLA ETF—Stocks Plus Built‑In Crash Protection
JPMorgan AM launched HOLA, an ETF that aims to generate income from foreign equities while mitigating risk through a laddered options overlay. 
Via Benzinga
Topics ETFs
AstraZeneca's Experimental Therapy Stumbles In Late-Stage Study For Rare Protein Deposit Condition
AstraZeneca's anselamimab missed the main goal in a Phase 3 AL amyloidosis trial but showed promising benefit in a defined patient subgroup. 
Via Benzinga
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk. 
Via Benzinga
Topics Government World Trade
GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026. 
Via Benzinga
AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial
AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a favorable safety profile. 
Via Benzinga
Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension
From AstraZeneca
Via Business Wire
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and a look at the catalysts that could be driving the attention. 
Via Benzinga
Why Is AbbVie Stock Trading Higher On Thursday?
AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data. 
Via Benzinga
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda's looming patent loss. 
Via Benzinga
Topics Intellectual Property
Dow Futures Edge Up As Trump Prepares More Tariff Letters: Freeport, UnitedHealth, Meta, Novo Nordisk, AstraZeneca Among Stocks In Focus
While Dow Jones futures edged up by 0.17% at the time of writing, the S&P 500 futures were up 0.15%. 
Via Stocktwits
Topics ETFs Government Stocks
Artelo Biosciences Analyst See It As An Emerging Biotech
Artelo gets Buy rating from Boral Capital after positive updates on ART27.13, ART26.12, and preclinical success of its candidate for depression. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.